德诺苏马布
医学
唑来膦酸
危险系数
内科学
肺癌
肿瘤科
不利影响
多发性骨髓瘤
泌尿科
外科
骨质疏松症
置信区间
作者
Giorgio V. Scagliotti,Vera Hirsh,Salvatore Siena,David H. Henry,Penella J. Woll,Christian Manegold,Philippe Solal‐Céligny,Gladys Rodriguez,Maciej Krzakowski,Nilesh Mehta,Lara Lipton,José Á. García-Sáenz,José Rodrigues Pereira,Kumar Prabhash,Tudor–Eliade Ciuleanu,Vladimir Kanarev,Huei Wang,Arun Balakumaran,Ira Jacobs
标识
DOI:10.1097/jto.0b013e31826aec2b
摘要
Denosumab, a fully human anti-RANKL monoclonal antibody, reduces the incidence of skeletal-related events in patients with bone metastases from solid tumors. We present survival data for the subset of patients with lung cancer, participating in the phase 3 trial of denosumab versus zoledronic acid (ZA) in the treatment of bone metastases from solid tumors (except breast or prostate) or multiple myeloma.Patients were randomized 1:1 to receive monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg. An exploratory analysis, using Kaplan-Meier estimates and proportional hazards models, was performed for overall survival among patients with non-small-cell lung cancer (NSCLC) and SCLC.Denosumab was associated with improved median overall survival versus ZA in 811 patients with any lung cancer (8.9 versus 7.7 months; hazard ratio [HR] 0.80) and in 702 patients with NSCLC (9.5 versus 8.0 months; HR 0.78) (p = 0.01, each comparison). Further analysis of NSCLC by histological type showed a median survival of 8.6 months for denosumab versus 6.4 months for ZA in patients with squamous cell carcinoma (HR 0.68; p = 0.035). Incidence of overall adverse events was balanced between treatment groups; serious adverse events occurred in 66.0% of denosumab-treated patients and 72.9% of ZA-treated patients. Cumulative incidence of osteonecrosis of the jaw was similar between groups (0.7% denosumab versus 0.8% ZA). Hypocalcemia rates were 8.6% with denosumab and 3.8% with ZA.In this exploratory analysis, denosumab was associated with improved overall survival compared with ZA, in patients with metastatic lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI